Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiovascular Prevention Clear all
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

NCT00679588
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin Sodium, Enoxaparin sodium, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Corlton, California • Huntingdon Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients

NCT01167569
View directory record Official record
Conditions
Reperfusion Injury
Interventions
Ascorbic Acid, 5 % Dextrose Water or Normal Saline
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 20, 2026, 2:42 PM EDT
Completed No phase listed Observational

Telestroke for Comprehensive Transient Ischemic Attack Care in Acute Stroke Ready Hospitals

NCT03724110
View directory record Official record
Conditions
Transient Ischemic Attack
Interventions
Telestroke
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Burnsville, Minnesota • Grand Rapids, Minnesota • Hibbing, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 20, 2026, 2:42 PM EDT
Terminated Phase 3 Interventional Results available

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion

NCT01349491
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Ranolazine, Matching placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Sep 20, 2026, 2:42 PM EDT
Completed No phase listed Observational

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

NCT02687867
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Dabigatran (Pradaxa), Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 20, 2026, 2:42 PM EDT
Completed No phase listed Observational

Family Cardiac Caregiver Investigation to Evaluate Outcomes

NCT00990548
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Yoga and Cardiovascular Exercise on Smoking Motivation

NCT01423578
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Hatha Yoga (HY), Cardiovascular Exercise (CE), Smoking Cessation Counseling
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma

NCT01050153
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Dalteparin sodium, Dalteparin sodium/aspirin
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Not applicable Interventional

The SCULPT-Job Cohort Study

NCT06965075
View directory record Official record
Conditions
Weight Maintenance, Weight Loss, Stress, Psychological, Job Stress, Diabetes Prevention, Obesity, Cardiovascular Risk Factor, Cardiovascular Diseases
Interventions
Diabetes Prevention Program
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Behavioral CVD Prevention Using Informatics

NCT02752464
View directory record Official record
Conditions
Health Behavior
Interventions
Counseling, feedback report
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation

NCT01493557
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
pantoprazole, Pradaxa (dabigatran etexilate), Pradaxa, within 30 minutes after a meal
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
81
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

NCT04070326
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Lanadelumab
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Santa Monica, California • Walnut Creek, California • Centennial, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT02584959
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
C1 esterase inhibitor [human] liquid, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 20, 2026, 2:42 PM EDT
Completed No phase listed Observational

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

NCT07417618
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, ASCVD
Interventions
Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60,000 participants
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 20, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

NCT07498517
View directory record Official record
Conditions
Thrombosis
Interventions
Placebo, Gruticibart, Ultrasound, Biopspecimen collection
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Community-based Approaches to Treating Hypertension and Colon Cancer Prevention

NCT01092078
View directory record Official record
Conditions
Hypertension, Colon Cancer
Interventions
MINT, Patient Navigation
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older · Male only
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 20, 2026, 2:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Team Lifestyle Immersion Hypertension Control Project

NCT07201948
View directory record Official record
Conditions
Hypertension
Interventions
Lifestyle Immersion Intervention that will address Nutrition, Physical Fitness, and BP Self-Monitoring3 Elements:
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
30 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

NCT00586521
View directory record Official record
Conditions
Hematologic Disease, Hemophilia A
Interventions
Kogenate (BAY14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
30 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 20, 2026, 2:42 PM EDT
Recruiting Phase 4 Interventional

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

NCT07609940
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Baton Rouge, Louisiana • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Not applicable Interventional Results available

Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome

NCT03170375
View directory record Official record
Conditions
Heart Failure
Interventions
Performance of WHEELS-I in promoting DASH/SRD adoption
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures

NCT00042081
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CGT003 (E2F Duplex Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
154
States / cities
Birmingham, Alabama • Daly City, California • Los Angeles, California + 89 more
Source: ClinicalTrials.gov public record
Updated May 4, 2006 · Synced Sep 20, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

NCT00001830
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hodgkin's Disease, Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions
Th2 cells in allo HSCTT, Th2 Cells
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 20, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

NCT03246906
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Mycophenolate Mofetil, Sirolimus
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 20, 2026, 2:42 PM EDT